Risk classification and nivolumab plus ipilimumab combination therapy for treatment of renal cell carcinoma

Mototsugu Oya, Yohei Tajima, Koki Kabu

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Risk classification and nivolumab plus ipilimumab combination therapy for treatment of renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences